Meeting
2019 ASCO Annual Meeting
Integrative molecular analysis of metastatic Merkel cell carcinoma to identify predictive biomarkers of response to avelumab.
Authors
Sara Georges
Global Development, EMD Serono Research & Development Inc., Billerica, MA
Sara Georges , Parantu K. Shah , Irina Shapiro , Christine Hicking , Lei Lu , Meliessa Hennessy , Sandra P. D'Angelo , Ti Cai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Biologic Correlates
Clinical Trial Registration Number
NCT02155647
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9569)
DOI
10.1200/JCO.2019.37.15_suppl.9569
Abstract #
9569
Poster Bd #
140
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Exploratory biomarker analysis in avelumab-treated patients with metastatic Merkel cell carcinoma progressed after chemotherapy.
First Author: Irina Shapiro
Poster
2015 ASCO Annual Meeting
A phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab (MSB0010718C) in patients with metastatic Merkel cell carcinoma.
First Author: Howard Kaufman
Poster
2022 ASCO Annual Meeting
Distinct mutational landscapes characterize melanomas metastatic to different anatomical sites.
First Author: Mahesh Y. Iddawela
Poster
2022 ASCO Annual Meeting
WDR49 mutation as a novel predictive biomarker in patients with non–small cell lung cancer with immune checkpoint inhibitors.
First Author: Zhihui Shi